Longitude Capital is a healthcare-focused venture capital firm specializing in venture growth investments in biotechnology, medical technology, and health solutions companies. The firm invests in both privately held and publicly traded companies across clinical and commercial stages.
36% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (3 deals in the last 12 months vs 6 prior). Average disclosed round size is $87.1M (across 127 rounds with reported amounts).
Portfolio
87
Fund Size
$585M
Top Stage
Series A
Last 12 Mo
3
Team
Juliet Bakker
Managing Director
Tim Qi
Venture Partner
Trudy Vanhove
Venture Partner
Teresa Cabreros
Director of Operations & Facilities
Zack Ely
Principal
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
142 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 cAMPfield Therapeutics | Series A | $180M | Jun 2026 |
| CcAMPfield | Series A | $180M | Jun 2026 |
 Ventaris Surgical | Series A | $30M | Jan 2026 |
 Aviceda | Series C | — | Jan 2026 |
| AAirNexis | Series A | $200M | Jan 2026 |
| CcAMPfield | Series A | $180M | Jan 2026 |
| cAMPfield Therapeutics | Series A | $180M | Jan 2026 |
| AAviceda Therapeutics | Unknown | $207.5M | Jan 2026 |
 MicroTransponder | Series F | $65M | Mar 2025 |
| AAviceda Therapeutics | Series C | — | Jan 2025 |
 FIRE1 | Unknown | $120M | Jan 2025 |
 Helicore Biopharma | Series A | $65M | Jan 2025 |
 Alentis Therapeutics | Series D | $181.4M | Nov 2024 |
| AAlentis | Series D | $181.4M | Nov 2024 |
| AAlpha-9 Oncology, Inc. | Series C | $175M | Oct 2024 |
| AAlpha-9 | Series C | $175M | Oct 2024 |
| CCurasen | Series B | — | Sep 2024 |
 Endogenex | Series C | $88M | Jun 2024 |
 Zenas BioPharma | Series C | $200M | May 2024 |
 Endeavor Biomedicines | Unknown | $132.5M | Apr 2024 |
 Nalu | Series E | $65M | Mar 2024 |
 Cohere Health | Series C | $50M | Feb 2024 |
| Zenas BioPharma | Series C | $200M | Jan 2024 |
 OrsoBio | Series B | $67M | Jan 2024 |
| AAlpha-9 Oncology, Inc. | Series C | $175M | Jan 2024 |
Page 1 of 6
Top Co-Investors
RA Capital Management31 shared
Frazier Healthcare Partners20 shared
Omega Funds18 shared
OrbiMed18 shared
Frazier Life Sciences15 shared
Novo Capital15 shared
Sofinnova Partners13 shared
Enavate Sciences11 shared
Medicxi11 shared
Rock Springs Capital11 shared
Endeavour Vision10 shared
Bain Capital Life Sciences9 shared
Pivotal Life Sciences9 shared
Gilde Healthcare9 shared
Samsara BioCapital9 shared
Aperture Venture Partners8 shared
Polaris Partners8 shared
Deerfield8 shared
Venrock8 shared
F-Prime Capital8 shared
Last updated: 20 October 2026